Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker ANIK · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Jun 24, 2026 | Integrity Implant System Post Market Clinical Follow-Up Study NCT06741527 · Rotator Cuff Tears of the Shoulder Integrity Implant System | ANIK Anika Therapeutics, Inc. | Not applicable | Recruiting | 150 | Jun 2027 | Registry ↗ |
| Apr 15, 2026 | HyaloFAST Trial for Repair of Articular Cartilage in the Knee NCT02659215 · Defect of Articular Cartilage Hyalofast, Microfracture | ANIK Anika Therapeutics, Inc. | Not applicable | Active, not recruiting | 200 | Mar 20, 2025 | Registry ↗ |
| Jan 28, 2025 | MONOVISC for Ankle Joint Pain Relief Due to Osteoarthritis NCT04204278 · Osteoarthritis Ankle Monovisc | ANIK Anika Therapeutics, Inc. | Not applicable | Completed | 25 | Feb 26, 2021 | Registry ↗ |
| Jan 28, 2025 | MONOVISC for Shoulder Joint Pain Relief Due to Osteoarthritis NCT04204265 · Osteo Arthritis Shoulders Monovisc | ANIK Anika Therapeutics, Inc. | Not applicable | Completed | 25 | Feb 26, 2021 | Registry ↗ |
| Jan 28, 2025 | MONOVISC for Hip Joint Pain Relief Due to Osteoarthritis NCT04204083 · Osteoarthritis, Hip Monovisc | ANIK Anika Therapeutics, Inc. | Not applicable | Completed | 25 | Feb 26, 2021 | Registry ↗ |
| Dec 16, 2024 | Study of Cingal® for Symptomatic Relief of Osteoarthritis of Ankle Joint NCT04640974 · Osteoarthritis, Ankle Cingal | ANIK Anika Therapeutics, Inc. | Not applicable | Completed | 25 | Sep 24, 2021 | Registry ↗ |
| Dec 16, 2024 | Study of Cingal® for Symptomatic Relief of Osteoarthritis of Shoulder Joint NCT04640961 · Osteoarthritis, Shoulder Cingal | ANIK Anika Therapeutics, Inc. | Not applicable | Completed | 25 | Sep 10, 2021 | Registry ↗ |
| Dec 16, 2024 | Study of Cingal® for Symptomatic Relief of Osteoarthritis of Hip Joint NCT04640298 · Osteoarthritis, Hip Cingal | ANIK Anika Therapeutics, Inc. | Not applicable | Completed | 25 | Sep 10, 2021 | Registry ↗ |
| Aug 9, 2023 | Study of Cingal® and Triamcinolone Hexacetonide for the Relief of Knee Osteoarthritis Pain NCT04231318 · Osteoarthritis, Knee Cingal, Triamcinolone Hexacetonide (TH) | ANIK Anika Therapeutics, Inc. | Phase 3 | Completed | 231 | May 16, 2022 | Registry ↗ |
| Jul 11, 2023 | Safety and Effectiveness of Monovisc® Injection for Osteoarthritis of the Knee NCT00653432 · Osteoarthritis Monovisc®, Saline | ANIK Anika Therapeutics, Inc. | Not applicable | Completed | 369 | Dec 2009 | Registry ↗ |
| Jun 1, 2023 | Cingal Study for Knee Osteoarthritis NCT01891396 · Knee Osteoarthritis Hyaluronic Acid and TH (Cingal®), Hyaluronic Acid (Monovisc… | ANIK Anika Therapeutics, Inc. | Not applicable | Completed | 368 | May 2014 | Registry ↗ |
| May 31, 2023 | Study of Cingal for the Relief of Knee Osteoarthritis Compared to Triamcinolone Hexacetonide at 39… NCT03390036 · Knee Osteoarthritis Cingal, Monovisc | ANIK Anika Therapeutics, Inc. | Phase 3 | Completed | 526 | Jul 30, 2018 | Registry ↗ |
| Nov 30, 2022 | Study of Sodium Hyaluronate to Provide Symptomatic Relief of Lateral Epicondylosis (Tennis Elbow) NCT02861183 · Epicondylitis, Tennis Elbow OVT (Sodium Hyaluronate), Saline | ANIK Anika Therapeutics, Inc. | Not applicable | Withdrawn | 0 | Apr 2027 | Registry ↗ |
| Mar 22, 2022 | Repeat Injection of Cingal® for Osteoarthritis of the Knee NCT02381652 · Osteoarthritis of the Knee Cingal, Cingal | ANIK Anika Therapeutics, Inc. | Phase 3 | Completed | 242 | Apr 2015 | Registry ↗ |
| Feb 24, 2022 | Study of Cingal™ for the Relief of Knee Osteoarthritis Compared to Triamcinolone Hexacetonide NCT03191903 · Knee Osteoarthritis Cingal, Monovisc | ANIK Anika Therapeutics, Inc. | Phase 3 | Completed | 576 | Apr 23, 2018 | Registry ↗ |
| Dec 8, 2021 | OVT for Epicondylosis (Tennis Elbow) NCT04026191 · Epicondylitis, Lateral, Tendinopathy, Elbow OrthoVisc®-T (OVT) | ANIK Anika Therapeutics, Inc. | Not applicable | Completed | 50 | Dec 31, 2020 | Registry ↗ |
| Oct 17, 2017 | Safety Study of Cosmetic Tissue Augmentation in People of Color NCT01147172 · Wrinkles Elevess | ANIK Anika Therapeutics, Inc. | Not applicable | Completed | 100 | Dec 2009 | Registry ↗ |
17 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 8:22 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances